Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1719–1729. doi: 10.1038/bjc.1996.621

Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.

G Lehne 1, P De Angelis 1, O P Clausen 1, H E Rugstad 1
PMCID: PMC2077210  PMID: 8956784

Abstract

Drug resistance is a major obstacle to successful chemotherapy of primary liver cancer, which is associated with high expression of the multidrug resistance (MDR) gene product P-glycoprotein (Pgp), a multidrug efflux transporter. The most effective single agents in treatment of primary liver carcinoma belong to the anthracycline family, yet several anthracyclines are known to be substrates for Pgp. In the present study, we compared four anthracyclines with respect to cell growth inhibition, intracellular accumulation and cellular efflux using the HB8065/R human hepatoma cell line which is rich in Pgp, and the Pgp-poor parental line HB8065/S. The anthracyclines were also administered in conjunction with the Pgp-modifying agents verapamil and SDZ PSC 833 to assess modulation of resistance. The HB8065/R cells were sensitive to aclarubicin (ACL) and highly resistant to epirubicin (EPI), doxorubicin (DOX) and daunorubicin (DNR). SDZ PSC 833 enhanced accumulation, decreased efflux and increased cytotoxicity of EPI, DOX and DNR in the HB8065/R cells, but none of these effects was seen with ACL. In conclusion, ACL is apparently not transported by Pgp and retains its activity in a multidrug-resistant human hepatoma cell line; such properties can be exploited for clinical purposes.

Full text

PDF
1719

Images in this article

1724Figure 5
on p.1724

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aden D. P., Fogel A., Plotkin S., Damjanov I., Knowles B. B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979 Dec 6;282(5739):615–616. doi: 10.1038/282615a0. [DOI] [PubMed] [Google Scholar]
  2. Bachur N. R., Steele M., Meriwether W. D., Hildebrand R. C. Cellular pharmocodynamics of several anthrocycline antibiotics. J Med Chem. 1976 May;19(5):651–654. doi: 10.1021/jm00227a015. [DOI] [PubMed] [Google Scholar]
  3. Bates D. A., Fung H., Mackillop W. J. Adriamycin uptake, intracellular binding and cytotoxicity in Chinese hamster ovary cells. Cancer Lett. 1985 Sep 15;28(2):213–221. doi: 10.1016/0304-3835(85)90077-1. [DOI] [PubMed] [Google Scholar]
  4. Bates S. E., Zhan Z., Dickstein B., Lee J. S., Scala S., Fojo A. T., Paull K., Wilson W. Reversal of multidrug resistance. J Hematother. 1994 Fall;3(3):219–223. doi: 10.1089/scd.1.1994.3.219. [DOI] [PubMed] [Google Scholar]
  5. Batist G., Tulpule A., Sinha B. K., Katki A. G., Myers C. E., Cowan K. H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986 Nov 25;261(33):15544–15549. [PubMed] [Google Scholar]
  6. Beppu T., Ohara C., Yamaguchi Y., Ichihara T., Yamanaka T., Katafuchi S., Ikei S., Mori K., Fukushima S., Nakano M. A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer. 1991 Dec 15;68(12):2555–2560. doi: 10.1002/1097-0142(19911215)68:12<2555::aid-cncr2820681204>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  7. Bhalla K., Hindenburg A., Taub R. N., Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res. 1985 Aug;45(8):3657–3662. [PubMed] [Google Scholar]
  8. Boesch D., Gavériaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991 Aug 15;51(16):4226–4233. [PubMed] [Google Scholar]
  9. Brock I., Hipfner D. R., Nielsen B. S., Jensen P. B., Deeley R. G., Cole S. P., Sehested M. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res. 1995 Feb 1;55(3):459–462. [PubMed] [Google Scholar]
  10. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992 Jan 15;79(2):473–476. [PubMed] [Google Scholar]
  11. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  12. Chan H. S., Thorner P. S., Haddad G., Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990 Apr;8(4):689–704. doi: 10.1200/JCO.1990.8.4.689. [DOI] [PubMed] [Google Scholar]
  13. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  14. Cole S. P., Chanda E. R., Dicke F. P., Gerlach J. H., Mirski S. E. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 1991 Jul 1;51(13):3345–3352. [PubMed] [Google Scholar]
  15. Coley H. M., Twentyman P. R., Workman P. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer. 1990;26(6):665–667. doi: 10.1016/0277-5379(90)90112-7. [DOI] [PubMed] [Google Scholar]
  16. Coley H. M., Twentyman P. R., Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol. 1989 Dec 15;38(24):4467–4475. doi: 10.1016/0006-2952(89)90658-8. [DOI] [PubMed] [Google Scholar]
  17. Coley H. M., Twentyman P. R., Workman P. The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol. 1993 Oct 19;46(8):1317–1326. doi: 10.1016/0006-2952(93)90094-d. [DOI] [PubMed] [Google Scholar]
  18. Cornwell M. M., Pastan I., Gottesman M. M. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem. 1987 Feb 15;262(5):2166–2170. [PubMed] [Google Scholar]
  19. Dantchev D., Slioussartchouk V., Paintrand M., Hayat M., Bourut C., Mathé G. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin. Cancer Treat Rep. 1979 May;63(5):875–888. [PubMed] [Google Scholar]
  20. Egorin M. J., Hildebrand R. C., Cimino E. F., Bachur N. R. Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res. 1974 Sep;34(9):2243–2245. [PubMed] [Google Scholar]
  21. Egorin M. J., Van Echo D., Fox B. M., Whitacre M., Bachur N. R. Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemother Pharmacol. 1982;8(1):41–46. doi: 10.1007/BF00292870. [DOI] [PubMed] [Google Scholar]
  22. Eijdems E. W., de Haas M., Timmerman A. J., Van der Schans G. P., Kamst E., de Nooij J., Astaldi Ricotti G. C., Borst P., Baas F. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer. 1995 Jan;71(1):40–47. doi: 10.1038/bjc.1995.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  24. Falkson G., MacIntyre J. M., Moertel C. G., Johnson L. A., Scherman R. C. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1984 Sep 15;54(6):970–977. doi: 10.1002/1097-0142(19840915)54:6<970::aid-cncr2820540604>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  25. Foxwell B. M., Mackie A., Ling V., Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol. 1989 Oct;36(4):543–546. [PubMed] [Google Scholar]
  26. Friche E., Jensen P. B., Nissen N. I. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol. 1992;30(3):235–237. doi: 10.1007/BF00686321. [DOI] [PubMed] [Google Scholar]
  27. Frishman W., Kirsten E., Klein M., Pine M., Johnson S. M., Hillis L. D., Packer M., Kates R. Clinical relevance of verapamil plasma levels in stable angina pectoris. Am J Cardiol. 1982 Nov;50(5):1180–1184. doi: 10.1016/0002-9149(82)90440-4. [DOI] [PubMed] [Google Scholar]
  28. Hall K. S., Endresen L., Huitfeldt H. S., Rugstad H. E. Induction of in vitro resistance to 4'-epidoxorubicin and cis-dichlorodiammineplatinum in hepatoma cells. Anticancer Res. 1991 Mar-Apr;11(2):817–823. [PubMed] [Google Scholar]
  29. Hamada H., Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7785–7789. doi: 10.1073/pnas.83.20.7785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hori S., Shirai M., Hirano S., Oki T., Inui T., Tsukagoshi S., Ishizuka M., Takeuchi T., Umezawa H. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gan. 1977 Oct;68(5):685–690. [PubMed] [Google Scholar]
  31. Ichihara T., Sakamoto K., Mori K., Akagi M. Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer Res. 1989 Aug 1;49(15):4357–4362. [PubMed] [Google Scholar]
  32. Itsubo M., Ishikawa T., Toda G., Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer. 1994 Jan 15;73(2):298–303. doi: 10.1002/1097-0142(19940115)73:2<298::aid-cncr2820730211>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  33. Jensen P. B., Sørensen B. S., Sehested M., Demant E. J., Kjeldsen E., Friche E., Hansen H. H. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol. 1993 May 25;45(10):2025–2035. doi: 10.1016/0006-2952(93)90013-m. [DOI] [PubMed] [Google Scholar]
  34. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976 Nov 11;455(1):152–162. doi: 10.1016/0005-2736(76)90160-7. [DOI] [PubMed] [Google Scholar]
  35. Knowles B. B., Howe C. C., Aden D. P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980 Jul 25;209(4455):497–499. doi: 10.1126/science.6248960. [DOI] [PubMed] [Google Scholar]
  36. Lehne G., De Angelis P., Clausen O. P., Egeland T., Tsuruo T., Rugstad H. E. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry. 1995 Jul 1;20(3):228–237. doi: 10.1002/cyto.990200306. [DOI] [PubMed] [Google Scholar]
  37. Licht T., Pastan I., Gottesman M., Herrmann F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol. 1994 Oct;69(4):159–171. doi: 10.1007/BF02215949. [DOI] [PubMed] [Google Scholar]
  38. Machover D., Gastiaburu J., Delgado M., Goldschmidt E., Hulhoven R., Misset J. L., de Vassal F., Tapiero H., Ribaud P., Schwarzenberg L. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Cancer Treat Rep. 1984 Jun;68(6):881–886. [PubMed] [Google Scholar]
  39. Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991 Aug 1;78(3):586–592. [PubMed] [Google Scholar]
  40. Martini A., Moro E., Pacciarini M. A., Tamassia V., Natale N., Piazza E. Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients. Int J Clin Pharmacol Res. 1984;4(3):231–238. [PubMed] [Google Scholar]
  41. Meriwether W. D., Bachur N. R. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res. 1972 Jun;32(6):1137–1142. [PubMed] [Google Scholar]
  42. Millot J. M., Rasoanaivo T. D., Morjani H., Manfait M. Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells. Br J Cancer. 1989 Nov;60(5):678–684. doi: 10.1038/bjc.1989.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Mimnaugh E. G., Dusre L., Atwell J., Myers C. E. Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells. Cancer Res. 1989 Jan 1;49(1):8–15. [PubMed] [Google Scholar]
  44. Mortensen S. A. Aclarubicin: preclinical and clinical data suggesting less chronic cardiotoxicity compared with conventional anthracyclines. Eur J Haematol Suppl. 1987;47:21–31. doi: 10.1111/j.1600-0609.1987.tb00019.x. [DOI] [PubMed] [Google Scholar]
  45. Muggia F. M., Green M. D. New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol. 1991;11(1):43–64. doi: 10.1016/1040-8428(91)90017-7. [DOI] [PubMed] [Google Scholar]
  46. Mülder H. S., Dekker H., Pinedo H. M., Lankelma J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochem Pharmacol. 1995 Sep 28;50(7):967–974. doi: 10.1016/0006-2952(95)00221-k. [DOI] [PubMed] [Google Scholar]
  47. Oki T., Takeuchi T., Oka S., Umezawa H. New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. Recent Results Cancer Res. 1981;76:21–40. doi: 10.1007/978-3-642-81565-2_4. [DOI] [PubMed] [Google Scholar]
  48. Okuyama T., Maehara Y., Endo K., Baba H., Adachi Y., Kuwano M., Sugimachi K. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer. 1994 Aug 15;74(4):1230–1236. doi: 10.1002/1097-0142(19940815)74:4<1230::aid-cncr2820740409>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  49. Paul C., Liliemark J., Tidefelt U., Gahrton G., Peterson C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit. 1989;11(2):140–148. doi: 10.1097/00007691-198903000-00004. [DOI] [PubMed] [Google Scholar]
  50. Pedersen-Bjergaard J., Brincker H., Ellegaard J., Drivsholm A., Freund L., Jensen K. B., Jensen M. K., Nissen N. I. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep. 1984 Oct;68(10):1233–1238. [PubMed] [Google Scholar]
  51. Scott C. A., Westmacott D., Broadhurst M. J., Thomas G. J., Hall M. J. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Br J Cancer. 1986 May;53(5):595–600. doi: 10.1038/bjc.1986.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sehested M., Skovsgaard T., van Deurs B., Winther-Nielsen H. Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst. 1987 Jan;78(1):171–179. doi: 10.1093/jnci/78.1.171. [DOI] [PubMed] [Google Scholar]
  53. Streeter D. G., Johl J. S., Gordon G. R., Peters J. H. Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells. Cancer Chemother Pharmacol. 1986;16(3):247–252. doi: 10.1007/BF00293986. [DOI] [PubMed] [Google Scholar]
  54. Tarasiuk J., Frézard F., Garnier-Suillerot A., Gattegno L. Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta. 1989 Sep 19;1013(2):109–117. doi: 10.1016/0167-4889(89)90038-4. [DOI] [PubMed] [Google Scholar]
  55. Weaver J. L., Pine P. S., Aszalos A., Schoenlein P. V., Currier S. J., Padmanabhan R., Gottesman M. M. Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells. Exp Cell Res. 1991 Oct;196(2):323–329. doi: 10.1016/0014-4827(91)90267-x. [DOI] [PubMed] [Google Scholar]
  56. Yuen A. R., Sikic B. I. Multidrug resistance in lymphomas. J Clin Oncol. 1994 Nov;12(11):2453–2459. doi: 10.1200/JCO.1994.12.11.2453. [DOI] [PubMed] [Google Scholar]
  57. Zenebergh A., Baurain R., Trouet A. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin. Cancer Chemother Pharmacol. 1982;8(2):243–249. doi: 10.1007/BF00255491. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES